{"schema_version":"secwatch.filing_event.v1","accession":"0001599298-25-000066","form_type":"8-K","ticker":"SMMT","cik":"0001599298","company_name":"Summit Therapeutics Inc.","filed_at":"2025-04-25T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.956691+00:00","generated_at":"2026-05-23T05:51:56.839879+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Summit: Ivonescimab gets second NMPA approval in China; OS hazard ratio 0.777","bullets":["NMPA approved ivonescimab for front-line PD-L1+ advanced NSCLC based on HARMONi-2 Phase III trial.","Interim OS analysis showed hazard ratio 0.777 (22% reduction in risk of death) at 39% data maturity.","Primary endpoint PFS previously showed HR 0.51 (p<0.0001) favoring ivonescimab over pembrolizumab.","Summit is enrolling HARMONi-7, a multiregional Phase III trial of ivonescimab vs pembrolizumab in same population."],"urls":{"canonical":"https://secwatch.observer/filing/0001599298-25-000066","json":"https://secwatch.observer/filing/0001599298-25-000066.json","markdown":"https://secwatch.observer/filing/0001599298-25-000066.md","text":"https://secwatch.observer/filing/0001599298-25-000066.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1599298/000159929825000066/0001599298-25-000066-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1599298/000159929825000066/smmt-20250425.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T05:51:56.839879+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}